Cullinan Therapeutics (CGEM.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Dec8

Cullinan Therapeutics' CLN-049 Monotherapy Shows Promise in Phase 1

16:17

Cullinan Therapeutics presents clinical data of FLT3xCD3 T-cell engager CLN-049

15:38

Dec1

Cullinan Therapeutics Inc. Receives FDA Fast Track Designation for CLN-049

12:00

Nov26

JonesTrading Analyst Reiterates Buy Rating for Cullinan Therapeutics

14:57

Nov24

BTIG Maintains Buy Rating and Raises Target Price for Cullinan Therapeutics to $38

18:36

Nov22

Wedbush sets $25 price target for Cullinan Therapeutics

04:16

Schedules & Filings

Schedules

Filings

Nov6

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Net Income -50.61 M, EPS -0.8567

Aug7

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -70.06 M, EPS -1.187

May8

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income -48.5 M, EPS -0.8233

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More